BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple presentations at the American ...
13d
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small ...
Detailed price information for Bridgebio Oncology Therapeutics Inc (BBOT-Q) from The Globe and Mail including charting and trades.
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) used a presentation at Leerink Partners’ Global Healthcare Conference to outline its strategy around “next-generation RAS therapeutics,” highlighting thre ...
Detailed price information for Bridgebio Oncology Therapeutics Inc (BBOT-Q) from The Globe and Mail including charting and trades.
BBO-8520 monotherapy in patients with KRAS G12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results